Supernus Pharmaceuticals Inc (SUPN) reports robust revenue growth and strategic advancements, despite facing market ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s ...

The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...

On a per-share basis, the Rockville, Maryland-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and stock option expense, were 75 cents per share.

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full yea ...

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) will likely be releasing its earnings data after the market closes ...

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...